Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Next Previous
Search
Trial Profile

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durlobactam/sulbactam (Primary)
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Entasis Therapeutics

    • Most Recent Events

    • 16 Dec 2019 Results assessing the tolerability and PK of SUL-DUR in patients with cUTI, including acute pyelonephritis (AP) published in the Antimicrobial Agents and Chemotherapy
    • 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
    • 14 Aug 2018 According to an Entasis Therapeutics media release, the company plans to present additional detail from this trial at an upcoming medical conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top